Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 14,400 shares, a decrease of 20.0% from the February 29th total of 18,000 shares. Based on an average trading volume of 104,500 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.4% of the company’s stock are sold short.
Hedge Funds Weigh In On Salarius Pharmaceuticals
A number of hedge funds have recently modified their holdings of SLRX. Armistice Capital LLC boosted its holdings in Salarius Pharmaceuticals by 105.2% in the third quarter. Armistice Capital LLC now owns 225,000 shares of the company’s stock worth $148,000 after purchasing an additional 115,364 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Salarius Pharmaceuticals by 17.9% in the third quarter. Renaissance Technologies LLC now owns 634,261 shares of the company’s stock worth $124,000 after purchasing an additional 96,200 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in Salarius Pharmaceuticals by 1,350.2% in the second quarter. Millennium Management LLC now owns 291,900 shares of the company’s stock worth $61,000 after purchasing an additional 271,772 shares in the last quarter. 11.88% of the stock is owned by institutional investors and hedge funds.
Salarius Pharmaceuticals Stock Up 9.0 %
NASDAQ SLRX opened at $0.53 on Monday. Salarius Pharmaceuticals has a 1-year low of $0.43 and a 1-year high of $2.68. The firm’s fifty day simple moving average is $0.58 and its 200-day simple moving average is $0.65.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Read More
- Five stocks we like better than Salarius Pharmaceuticals
- When to Sell a Stock for Profit or Loss
- Is Rumble Revving Up for Growth or Just Sputtering?
- Most Volatile Stocks, What Investors Need to Know
- Keurig Dr Pepper Reaffirms Its Guidance, Time to Buy?
- Insider Buying Explained: What Investors Need to Know
- 4 Dividend Aristocrats Trading at a Discount
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
